Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: ISRAEL

Sector: Medical Devices

InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Website: inspiremd.com


  • Good financial results growth rate 25.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (14.6%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 286.1% (LTM)
  • Share price is 69.2% higher than minimum and 56.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (1.4x vs 1.0x)
  • For the last 3 months insiders sold company shares on $0.1 mln (-0.522% of cap.)

Key Financials (Download financials)

Ticker: NSPR
Share price, USD:  (0.0%)1.65
year average price 2.3300  


year start price 2.9500 2025-02-15

max close price 3.7000 2025-02-24

min close price 1.5800 2026-01-13

current price 1.6500 2026-02-14
Common stocks: 7 838 506

Dividend Yield:  0.0%
EV / Sales: -7.1x
Margin (EBITDA LTM / Revenue): -511.1%

Target EV / EBITDA (hist percentile): 1.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 13
Net Debt ($m): -77
EV (Enterprise Value): -64
EBITDA LTM (млн $): -46
Price to Book: 0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-24globenewswire.com

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

2025-11-19globenewswire.com

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

2025-07-11zacks.com

InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

2025-05-09seekingalpha.com

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

2025-05-09zacks.com

InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

2024-12-11zacks.com

NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study

2024-11-08globenewswire.com

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2024-09-17zacks.com

NSPR Stock Declines Despite PMA Application Submission for CGuard

2024-08-06zacks.com

InspireMD, Inc. (NSPR) Reports Q2 Loss, Misses Revenue Estimates

2024-08-06globenewswire.com

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-10 2025-08-04 2024-11-12 2024-08-05 2024-05-13 2023-11-06 2023-08-07 2023-05-15 2022-11-07
acceptedDate 2025-11-10 16:06:11 2025-08-04 16:05:56 2025-03-12 06:05:57 2024-11-12 09:00:35 2024-08-05 16:30:53 2024-05-13 16:15:41 2024-03-05 16:05:37 2023-11-06 16:05:55 2023-08-07 17:25:43 2023-05-15 16:06:21 2023-03-30 08:02:24 2022-11-07 16:05:52 2022-03-07 16:25:13 2021-03-08 16:01:36
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 3M 2M 7M 2M 2M 2M 6M 2M 2M 1M 5M 1M 4M 2M
costOfRevenue 2M 1M 6M 1M 1M 1M 4M 1M 1M 866 000 4M 1M 4M 2M
grossProfit 864 000 313 000 2M 414 000 331 000 292 000 2M 438 000 491 000 373 000 1M 366 000 754 000 83 000
grossProfitRatio 0.342 0.176 0.229 0.19 0.193 0.281 0.298 0.301 0.256
researchAndDevelopmentExpenses 4M 4M 14M 4M 3M 3M 8M 2M 2M 2M 8M 2M 5M 2M
generalAndAdministrativeExpenses 6M 5M 15M 3M 4M 4M 11M 3M 3M 2M 8M 2M 7M 6M
sellingAndMarketingExpenses 4M 4M 6M 1M 1M 1M 4M 876 000 892 000 788 000 4M 845 000 3M 2M
sellingGeneralAndAdministrativeExpenses 10M 9M 21M 5M 5M 5M 15M 4M 4M 3M 12M 3M 10M 8M
otherExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
operatingExpenses 14M 13M 35M 9M 9M 8M 23M 6M 6M 5M 20M 5M 15M 10M
costAndExpenses 16M 15M 41M 10M 10M 9M 27M 7M 7M 6M 24M 6M 19M 13M
interestIncome 0 0 2M 572 000 351 000 382 000 1M 461 000 238 000 125 000 250 000 0 0 0
interestExpense 0 132 000 0 0 0 0 0 0 0 -125 000 0 81 000 157 000 160 000
depreciationAndAmortization 107 000 107 000 280 000 70 000 66 000 69 000 232 000 58 000 58 000 55 000 188 000 50 000 161 000 151 000
ebitda -13M -13M -33M -8M -8M -7M -21M -6M -5M -4M -19M -5M -15M -10M
ebitdaratio -4.994 -7.262 -4.636 -4.712 -4.861 -3.624 -3.188 -3.492 -3.187
operatingIncome -13M -13M -34M -8M -8M -7M -21M -6M -5M -4M -19M -5M -15M -10M
operatingIncomeRatio -5.173 -7.322 -4.675 -4.75 -4.907 -3.624 -3.223 -3.536 -3.222
totalOtherIncomeExpensesNet 343 000 -132 000 2M 9M 351 000 382 000 1M 461 000 238 000 125 000 250 000 81 000 -157 000 -160 000
incomeBeforeTax -13M -13M -32M 572 000 -8M -7M -20M -5M -5M -4M -18M -5M -15M -11M
incomeBeforeTaxRatio -5.037 -7.397 0.316 -4.548 -4.654 -3.328 -3.079 -3.435 -3.165
incomeTaxExpense 0 0 59 000 0 0 25 724 65 000 -58 000 0 -125 000 28 000 -81 000 45 000 4000
netIncome -13M -13M -32M -8M -8M -7M -20M -5M -5M -4M -18M -4M -15M -11M
netIncomeRatio -5.037 -7.397 -4.359 -4.548 -4.654 -3.328 -3.079 -3.334 -3.108
eps -0.17 -0.26 -0.76 0.012 -0.22 -0.21 -0.82 -0.15 -0.24 -0.51 -2.35 -0.57 -2.03 -6.9
epsdiluted -0.17 -0.26 0.012 -0.22 -0.21 -0.15 -0.24 -0.51 -0.57
weightedAverageShsOut 73M 51M 42M 48M 36M 34M 24M 34M 21M 8M 8M 8M 7M 2M
weightedAverageShsOutDil 73M 51M 42M 48M 36M 34M 24M 34M 21M 8M 8M 8M 7M 2M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-12 2024-03-05 2023-03-30 2022-03-07 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 2M 1M 250 000 -157 000 -160 000
ebit -34M -21M -19M -15M -10M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -32M -20M -18M -15M -11M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -32M -20M -18M -15M -11M
epsDiluted -0.76 -0.82 -2.35 -2.03 -6.9

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-10 2025-08-04 2024-11-12 2024-08-05 2024-05-13 2023-11-06 2023-08-07 2023-05-15 2022-11-07
acceptedDate 2025-11-10 16:06:11 2025-08-04 16:05:56 2025-03-12 06:05:57 2024-11-12 09:00:35 2024-08-05 16:30:53 2024-05-13 16:15:41 2024-03-05 16:05:37 2023-11-06 16:05:55 2023-08-07 17:25:43 2023-05-15 16:06:21 2023-03-30 08:02:24 2022-11-07 16:05:52 2022-03-07 16:25:13 2021-03-08 16:01:36
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 63M 12M 19M 16M 28M 9M 10M 14M 12M 4M 5M 4M 12M 13M
shortTermInvestments 0 8M 16M 25M 19M 25M 29M 29M 35M 9M 13M 17M 22M 0
cashAndShortTermInvestments 63M 19M 35M 40M 47M 34M 39M 43M 47M 13M 18M 21M 34M 13M
netReceivables 2M 2M 2M 2M 2M 2M 2M 1M 2M 2M 1M 1M 1M 945 000
inventory 4M 3M 3M 2M 2M 2M 2M 2M 2M 2M 2M 1M 1M 1M
otherCurrentAssets 945 000 947 000 0 1M 717 000 531 000 0 -30 000 8M 11M 0 860 000 0 0
totalCurrentAssets 70M 25M 41M 46M 52M 39M 44M 47M 51M 17M 21M 25M 37M 15M
propertyPlantEquipmentNet 6M 6M 5M 3M 3M 3M 3M 2M 2M 2M 2M 3M 2M 2M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 -7M 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 996 000 964 000 964 999 951 000 847 000 7M 859 000 856 000 858 000 905 000 725 000
totalNonCurrentAssets 8M 8M 6M 4M 4M 4M 3M 3M 3M 3M 3M 3M 3M 2M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 78M 33M 47M 50M 56M 42M 48M 50M 54M 20M 25M 28M 40M 18M
accountPayables 2M 2M 1M 1M 927 000 659 000 939 000 600 000 768 000 607 000 659 000 404 000 893 000 236 000
shortTermDebt 0 917 000 0 546 000 538 000 549 000 0 497 000 418 000 417 000 0 416 000 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 9M 7M 3M 5M 6M 4M 2M 4M 4M 3M 2M 3M 2M 1M
totalCurrentLiabilities 11M 9M 8M 7M 7M 5M 6M 5M 5M 4M 5M 4M 4M 4M
longTermDebt 2M 3M 0 682 000 786 000 914 000 0 1M 970 000 1M 0 1M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 2M 1M 1M 1M 1M 1M 1M 1M 1M 995 000 1M 1M 910 000
totalNonCurrentLiabilities 4M 4M 3M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 2M 3M 2M 1M 1M 914 000 2M 1M 1M 1M 2M 2M 1M 1M
totalLiabilities 14M 13M 11M 9M 9M 7M 8M 7M 7M 6M 7M 6M 6M 6M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 4000 3000 3000 0 3000 2000 2000 2000 2000 1000 1000 1000 1000 0
retainedEarnings -291M -278M -254M -244M -236M -229M -222M -216M -211M -206M -202M -197M -183M -168M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 0 0 0 0 0
othertotalStockholdersEquity 355M 298M 286M 283M 264M 259M 258M 219M 219M
totalStockholdersEquity 64M 20M 36M 41M 47M 35M 40M 43M 47M 13M 17M 22M 34M 12M
totalEquity 64M 20M 36M 41M 47M 35M 40M 43M 47M 13M 17M 22M 34M 12M
totalLiabilitiesAndStockholdersEquity 78M 33M 50M 56M 42M 50M 54M 20M 28M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 78M 33M 47M 50M 56M 42M 48M 50M 54M 20M 25M 28M 40M 18M
totalInvestments 0 8M 16M 25M 19M 25M 29M 29M 29M 9M 13M 17M 22M 0
totalDebt 2M 3M 2M 1M 1M 1M 2M 1M 1M 1M 2M 2M 1M 1M
netDebt -61M -8M -17M -15M -27M -8M -8M -13M -10M -3M -3M -2M -11M -11M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-12 2024-03-05 2023-03-30 2022-03-07 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 2M 2M 1M 1M 476 000
otherReceivables 682 000 648 000 213 000 165 000 469 000
prepaids 1M 578 000 655 000 522 000 334 000
totalPayables 2M 1M 789 000 1M 325 000
otherPayables 255 000 190 000 130 000 155 000 89 000
accruedExpenses 2M 2M 2M 1M 2M
capitalLeaseObligationsCurrent 542 000 557 000 419 000 420 000 400 000
capitalLeaseObligationsNonCurrent 2M 1M 1M 781 000 999 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 290M 261M 219M 217M 180M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR NSPR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-10 2025-08-04 2024-11-12 2024-08-05 2024-05-13 2023-11-06 2023-08-07 2023-05-15 2022-11-07
acceptedDate 2025-11-10 16:06:11 2025-08-04 16:05:56 2025-03-12 06:05:57 2024-11-12 09:00:35 2024-08-05 16:30:53 2024-05-13 16:15:41 2024-03-05 16:05:37 2023-11-06 16:05:55 2023-08-07 17:25:43 2023-05-15 16:06:21 2023-03-30 08:02:24 2022-11-07 16:05:52 2022-03-07 16:25:13 2021-03-08 16:01:36
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -13M -13M -32M -8M -8M -7M -20M -5M -5M -4M -18M -5M -15M -11M
depreciationAndAmortization 128 000 107 000 280 000 70 000 66 000 69 000 232 000 58 000 58 000 55 000 188 000 50 000 161 000 151 000
deferredIncomeTax 0 0 0 0 0 0 0 -325 000 27 000 0 0 0 74 000 177 000
stockBasedCompensation 4M 3M 10M 2M 3M 3M 4M 2M 930 000 289 000 2M 657 000 2M 606 000
changeInWorkingCapital 325 000 1M 736 000 -420 000 980 000 -560 000 -801 000 -421 000 770 000 -1M 395 000 -1M -75 000 533 000
accountsReceivables -348 000 65 000 198 000 -421 000 -87 000 782 000 -1M 425 000 -53 000 -383 000 142 000 17 000 -748 000 347 000
inventory -553 000 -232 000 -464 000 -239 000 154 000 -254 000 -485 000 -157 000 8000 -76 000 -478 000 40 000 272 000 -179 000
accountsPayables 235 000 -209 000 315 000 12 000 268 000 -280 000 280 000 -168 000 161 000 -52 000 -234 000 -723 000 657 000 -410 000
otherWorkingCapital 991 000 2M 687 000 228 000 645 000 -808 000 609 000 -521 000 654 000 -503 000 965 000 -592 000 -256 000 775 000
otherNonCashItems 78 000 259 000 -1M 97 000 -222 000 2M -381 000 201 000 -33 000 95 000 14 000 -24 000 -28 000 -4000
netCashProvidedByOperatingActivities -9M -8M -22M -6M -4M -5M -16M -4M -3M -5M -16M -5M -13M -9M
investmentsInPropertyPlantAndEquipment -329 000 -576 000 -1M -421 000 -475 000 -195 000 -381 000 -96 000 -45 000 -25 000 -473 000 -226 000 -344 000 -88 000
acquisitionsNet 0 0 0 0 0 0 0 0 9000 0 0 0 0 22 000
purchasesOfInvestments 0 -5M -14M -12M 0 -2M -40M 0 -32M -3M -19M 0 -24M 0
salesMaturitiesOfInvestments 8M 11M 0 -13M 6M 7M 25M 7M 5M 7M 28M 0 2M 0
otherInvestingActivites -8000 -22 000 20M -19 000 -28 000 -18 000 -17 000 -26 000 3M
netCashUsedForInvestingActivites 8M 5M -6M 6M 5M 6M -27M 4M 3M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 38M 2M -18M 18M 0 0 38M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 15M 0 -965 000 18M 0 0 0 0 -103 000
netCashUsedProvidedByFinancingActivities 53M 2M -965 000 18M 0 0 38M 0 -103 000
effectOfForexChangesOnCash 50 000 0 51 000 22 000 -10000 -4000 -58 000 -49 000 -1000 -22 000 -131 000 -6000 -8000 4000
netChangeInCash 52M -874 000 9M -13M 19M -251 000 5M 2M 7M -404 000 -7M -2M -641 000 7M
cashAtEndOfPeriod 63M 12M 19M 16M 28M 9M 10M 14M 12M 4M 5M 4M 12M 13M
cashAtBeginningOfPeriod 12M 12M 10M 28M 9M 10M 5M 12M 4M 5M 12M 6M 13M 6M
operatingCashFlow -9M -8M -22M -6M -4M -5M -16M -4M -3M -5M -16M -5M -13M -9M
capitalExpenditure -329 000 -576 000 -1M -421 000 -475 000 -195 000 -381 000 -96 000 -45 000 -25 000 -473 000 -226 000 -344 000 -88 000
freeCashFlow -9M -9M -23M -6M -5M -5M -17M -4M -3M -5M -16M -5M -14M -9M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-12 2024-03-05 2023-03-30 2022-03-07 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 28M -67 000 -86 000 -113 000 -121 000
netCashProvidedByInvestingActivities 13M -16M 8M -22M -187 000
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 2M 38M 0 35M 16M
netCommonStockIssuance 2M 38M 0 35M 16M
commonStockIssuance 2M 38M 0 35M 16M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 17M 0 -140 000 0 0
netCashProvidedByFinancingActivities 18M 38M -140 000 35M 16M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-09 ET (fiscal 2025 q1)
2024 q4
2025-03-12 ET (fiscal 2024 q4)
2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-08-09 ET (fiscal 2024 q2)
2024 q1
2024-05-14 ET (fiscal 2024 q1)
2023 q4
2024-03-06 ET (fiscal 2023 q4)
2023 q3
2023-11-06 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-16 ET (fiscal 2023 q1)
2022 q4
2023-03-30 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-04 16:06 ET
InspireMD published news for 2025 q3
SEC form 8
2025-11-04 16:06 ET
InspireMD reported for 2025 q3
SEC form 8
2025-11-04 16:06 ET
InspireMD published news for 2025 q3
SEC form 10
2025-08-04 20:05 ET
InspireMD reported for 2025 q2
SEC form 8
2025-05-09 11:09 ET
InspireMD published news for 2025 q1
SEC form 8
2025-05-09 11:09 ET
InspireMD published news for 2025 q1
SEC form 10
2025-05-08 20:05 ET
InspireMD reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
InspireMD published news for 2025 q1
SEC form 8
2025-03-12 11:43 ET
InspireMD published news for 2024 q4
SEC form 8
2025-03-12 11:43 ET
InspireMD reported for 2024 q4
SEC form 10
2025-03-12 10:05 ET
InspireMD published news for 2024 q4
SEC form 10
2025-03-12 00:00 ET
InspireMD published news for 2024 q4
SEC form 10
2024-11-12 09:00 ET
InspireMD reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
InspireMD published news for 2024 q3
SEC form 8
2024-08-06 08:42 ET
InspireMD published news for 2024 q2
SEC form 8
2024-08-06 08:42 ET
InspireMD published news for 2024 q2
SEC form 10
2024-08-05 16:30 ET
InspireMD reported for 2024 q2
SEC form 10
2024-08-05 00:00 ET
InspireMD published news for 2024 q2
SEC form 8
2024-05-14 07:10 ET
InspireMD published news for 2024 q1
SEC form 8
2024-05-14 07:10 ET
InspireMD published news for 2024 q1
SEC form 10
2024-05-13 16:15 ET
InspireMD reported for 2024 q1
SEC form 10
2024-05-13 00:00 ET
InspireMD published news for 2024 q1
SEC form 8
2024-03-06 07:07 ET
InspireMD published news for 2023 q4
SEC form 8
2024-03-06 07:07 ET
InspireMD published news for 2023 q4
SEC form 10
2024-03-05 16:05 ET
InspireMD reported for 2023 q4
SEC form 10
2024-03-05 00:00 ET
InspireMD published news for 2023 q4
SEC form 10
2023-11-06 16:05 ET
InspireMD published news for 2023 q3
SEC form 8
2023-11-06 07:07 ET
InspireMD reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
InspireMD published news for 2023 q3
SEC form 6
2023-08-08 07:09 ET
InspireMD published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
InspireMD published news for 2023 q2
SEC form 10
2023-08-07 17:25 ET
InspireMD reported for 2023 q2
SEC form 10
2023-08-07 00:00 ET
InspireMD published news for 2023 q2
SEC form 6
2023-07-28 16:30 ET
InspireMD published news for 2023 q2
SEC form 6
2023-07-21 16:15 ET
InspireMD published news for 2023 q2
SEC form 6
2023-07-18 17:28 ET
InspireMD published news for 2023 q2
SEC form 6
2023-06-26 08:25 ET
InspireMD published news for 2023 q1
SEC form 6
2023-05-16 16:16 ET
InspireMD published news for 2023 q1
SEC form 6
2023-05-16 09:00 ET
InspireMD published news for 2023 q1
SEC form 8
2023-05-16 00:00 ET
InspireMD published news for 2023 q1
SEC form 6
2023-05-15 16:15 ET
InspireMD published news for 2023 q1
SEC form 10
2023-05-15 16:06 ET
InspireMD reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
InspireMD published news for 2023 q1
SEC form 6
2023-04-04 17:00 ET
InspireMD published news for 2023 q1
SEC form 6
2023-04-04 17:00 ET
InspireMD published news for 2023 q1
SEC form 10
2023-03-30 08:02 ET
InspireMD reported for 2022 q4
SEC form 6
2023-03-30 07:14 ET
InspireMD published news for 2022 q4
SEC form 10
2023-03-30 00:00 ET
InspireMD reported for 2022 q4
SEC form 8
2023-03-30 00:00 ET
InspireMD reported for 2022 q4
SEC form 6
2023-03-20 08:10 ET
InspireMD published news for 2022 q4
SEC form 6
2022-11-08 07:12 ET
InspireMD published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
InspireMD reported for 2022 q3
SEC form 10
2022-11-07 16:05 ET
InspireMD reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
InspireMD reported for 2022 q3
SEC form 6
2022-09-01 16:15 ET
InspireMD published news for 2022 q2
SEC form 6
2022-08-11 16:15 ET
InspireMD published news for 2022 q2
SEC form 8
2022-08-11 00:00 ET
InspireMD reported for 2022 q2
SEC form 10
2022-08-08 16:06 ET
InspireMD reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
InspireMD reported for 2022 q2
SEC form 6
2022-07-05 16:30 ET
InspireMD published news for 2022 q2
SEC form 6
2022-06-03 17:02 ET
InspireMD published news for 2022 q1
SEC form 6
2022-05-20 16:15 ET
InspireMD published news for 2022 q1
SEC form 6
2022-05-10 07:57 ET
InspireMD published news for 2022 q1
SEC form 8
2022-05-10 00:00 ET
InspireMD reported for 2022 q1
SEC form 10
2022-05-09 16:30 ET
InspireMD reported for 2022 q1
SEC form 10
2022-05-09 00:00 ET
InspireMD reported for 2022 q1
SEC form 6
2022-03-08 09:27 ET
InspireMD published news for 2021 q4
SEC form 8
2022-03-08 00:00 ET
InspireMD published news for 2021 q4
SEC form 10
2022-03-07 16:25 ET
InspireMD published news for 2021 q4
SEC form 10
2022-03-07 00:00 ET
InspireMD published news for 2021 q4
SEC form 6
2022-02-28 09:22 ET
InspireMD published news for 2021 q4
SEC form 6
2022-01-10 16:43 ET
InspireMD published news for 2021 q4
SEC form 6
2021-12-07 16:05 ET
InspireMD published news for 2021 q3
SEC form 6
2021-11-09 16:05 ET
InspireMD published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
InspireMD published news for 2021 q3
SEC form 10
2021-11-08 16:05 ET
InspireMD published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
InspireMD published news for 2021 q3
SEC form 6
2021-11-04 16:06 ET
InspireMD published news for 2021 q3
SEC form 6
2021-10-13 16:05 ET
InspireMD published news for 2021 q3
SEC form 6
2021-09-30 16:05 ET
InspireMD published news for 2021 q2
SEC form 6
2021-08-12 16:10 ET
InspireMD published news for 2021 q2
SEC form 6
2021-08-10 16:10 ET
InspireMD published news for 2021 q2
SEC form 8
2021-08-10 00:00 ET
InspireMD published news for 2021 q2
SEC form 10
2021-08-09 16:24 ET
InspireMD published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
InspireMD published news for 2021 q2
SEC form 6
2021-07-26 07:40 ET
InspireMD published news for 2021 q2
SEC form 6
2021-06-29 16:15 ET
InspireMD published news for 2021 q1
SEC form 6
2021-06-08 09:05 ET
InspireMD published news for 2021 q1
SEC form 6
2021-05-27 08:00 ET
InspireMD published news for 2021 q1
SEC form 6
2021-05-20 06:15 ET
InspireMD published news for 2021 q1
SEC form 6
2021-05-12 06:15 ET
InspireMD published news for 2021 q1
SEC form 6
2021-05-12 06:15 ET
InspireMD published news for 2021 q1
SEC form 6
2021-05-11 06:42 ET
InspireMD published news for 2021 q1
SEC form 6
2021-05-10 17:11 ET
InspireMD published news for 2021 q1
SEC form 10
2021-05-10 16:06 ET
InspireMD published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
InspireMD published news for 2021 q1
SEC form 6
2021-04-19 06:24 ET
InspireMD published news for 2021 q1
SEC form 6
2021-04-14 16:16 ET
InspireMD published news for 2021 q1
SEC form 6
2021-03-17 07:01 ET
InspireMD published news for 2020 q4
SEC form 6
2021-03-10 06:02 ET
InspireMD published news for 2020 q4
SEC form 10
2021-03-08 16:01 ET
InspireMD published news for 2020 q4
SEC form 6
2021-02-11 13:15 ET
InspireMD published news for 2020 q4
SEC form 6
2021-02-09 06:05 ET
InspireMD published news for 2020 q4
SEC form 6
2021-02-03 16:48 ET
InspireMD published news for 2020 q4
SEC form 6
2021-02-01 08:49 ET
InspireMD published news for 2020 q4
SEC form 6
2021-01-19 06:10 ET
InspireMD published news for 2020 q4
SEC form 6
2021-01-11 09:07 ET
InspireMD published news for 2020 q4
SEC form 6
2020-11-09 10:23 ET
InspireMD published news for 2020 q3
SEC form 10
2020-11-09 08:22 ET
InspireMD published news for 2020 q3
SEC form 6
2020-11-03 13:15 ET
InspireMD published news for 2020 q3
SEC form 6
2020-10-19 10:17 ET
InspireMD published news for 2020 q3
SEC form 6
2020-10-16 11:24 ET
InspireMD published news for 2020 q3
SEC form 6
2020-10-16 11:21 ET
InspireMD published news for 2020 q3
SEC form 6
2020-10-06 09:48 ET
InspireMD published news for 2020 q3